Brief: Dogwood Therapeutics Inc - Secures Royalty-Free License For Sp16 In All-Stock Deal With Serpin Pharma
29/09/2025 12:29
Sept 29 (Reuters) - Dogwood Therapeutics Inc DWTX.O: DOGWOOD THERAPEUTICS INC - SECURES ROYALTY-FREE LICENSE FOR SP16 IN ALL-STOCK DEAL WITH SERPIN PHARMA DOGWOOD THERAPEUTICS INC - SERPIN PHARMA TO RECEIVE 382,034 COMMON STOCK AND 179.1878 SHARES OF PREFERRED STOCK OF CO Source text: ID:nGNXjvqLW Further company coverage: DWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study